OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody ...
The addition of an investigational therapeutic cancer vaccine to first-line pembrolizumab exhibited activity among patients ...
Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the CABINET phase 3 pivotal trial evaluating CABOMETYX® (cabozantinib) versus placebo in patients with previously ...
Two doses of 52-week nerandomilast reduced FVC decline vs. placebo in the subgroup of U.S. adults with idiopathic pulmonary ...
Patients with untreated advanced melanoma do not appear to gain a survival advantage from the addition of a cancer vaccine to pembrolizumab, suggests a trial.
You can find over one million groups to join on LinkedIn, the social media network for professionals. Topics vary from discussions about how to think creatively to learning something new such as ...
One of the most recognized features of No Child Left Behind is subgroup analysis, which shifted attention from the average performance of a school to the performance of specific populations within a ...
These subgroup analyses add to the existing evidence of bempedoic acid as an effective treatment for the reduction of cardiovascular risk. MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Europe GmbH ...
Medulloblastoma is a highly malignant paediatric brain tumour classified into four biologically and clinically distinct molecular subgroups 1. The present clinical approach to medulloblastoma involves ...
Researchers at Maastricht University and the University of Copenhagen report that incorporating sweeteners and sweetness ...
The Department of Education plans to re-evaluate how many students’ test scores districts and schools will be permitted to exclude when determining whether they’ve met annual educational goals under ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback